Close this search box.

We are creating some awesome events for you. Kindly bear with us.

HKSTP’s Advancements in Regenerative Medicine

Image Credits: HKSTP, Press Release
Getting your Trinity Audio player ready...

Two partner companies associated with the Hong Kong Science and Technology Parks Corporation (HKSTP) have announced a collaborative effort to launch a regenerative medical project centred around Mesenchymal Stem Cells (MSCs) biology.

The project aims to address the increasing demand for osteoarthritis treatments in Hong Kong due to its ageing population. Osteoarthritis patients commonly suffer from joint pain, swelling, and “cracking” sounds in their bones, which can make simple tasks like climbing stairs unbearable. The prevalence of joint pain issues is significant, affecting nearly 17% of men and almost 24% of women aged 50 or above in the region.

The current non-surgical management of degenerative arthritis often involves the use of hyaluronic acid or corticosteroid injections, which may not be suitable for all patients. Surgical treatment primarily involves artificial joint replacement. However, the Hospital Authority has reported a considerable backlog of nearly 35,000 cases on the waiting list for full joint replacement surgeries in Hong Kong.

The rapid progress in regenerative medical technology offers promising possibilities for addressing osteoarthritis treatment. Currently, non-surgical management for osteoarthritis involves the use of hyaluronic acid or corticosteroid injections, but their suitability for all patients is uncertain, and concerns exist regarding potential side effects like cataracts, glaucoma, hypertension, diabetes, and osteoporosis associated with corticosteroids.

Surgical intervention often entails artificial joint replacement, but with almost 35,000 patients on the joint replacement waiting list in Hong Kong, suffering can persist while waiting. Moreover, artificial joints have a limited lifespan of around 20 years, necessitating careful consideration by doctors before treatment selection.

The advancement in regenerative medical technology has shown promise through the use of Mesenchymal Stem Cells (MSCs) for repairing degenerated joints, offering hope for osteoarthritis patients. MSCs can be sourced from various tissues such as bone marrow, the umbilical cord, and adipose tissue. Their functions include differentiation, proliferation, and tissue repair, making them a potential breakthrough in cellular therapy.

Currently, two methods of using stem cells are being explored. One involves harvesting a patient’s own stem cells from adipose tissue, culturing them outside the body, and reintroducing them to facilitate tissue repair. However, the high cost of this approach limits its accessibility to some patients.

The second and more promising method involves extracting MSCs from umbilical cords, subjecting them to cell culture and stringent quality testing in Japan, and then reintroducing them to the affected areas to promote tissue repair.

Stem cells’ ability to release secretome and extracellular vesicles during cultivation enhances various factors involved in tissue repair and regeneration, including cell proliferation and immune and inflammatory responses. These technological advancements offer new possibilities for effectively managing osteoarthritis and improving patients’ quality of life.

HKSTP’s “Medtech Co-Create” initiative brought together the two partner companies for a significant press conference named “Advancing Stem Cell Therapy: A Journey of Collaboration and Innovation” at Hong Kong Science Park. Supported by HKSTP, the two companies unveiled joint projects focused on regenerative medicine.

Their collaboration aims to raise public awareness about the potential of regenerative medicine while fostering its development in Hong Kong. Ultimately, the shared objective is to offer patients a secure, efficient, and minimally invasive treatment alternative through their efforts.

The CEO of HKSTP stated the organisation’s commitment to building a thriving world-class biomedical technology ecosystem in Hong Kong. He described the collaboration as exciting, as it aims to develop progressive treatments in regenerative medicine technology for the benefit of patients and to promote groundbreaking innovation in the biomedical industry. HKSTP is home to over 200 biotech companies, and the MTCC Programme fosters collaboration between park companies and corporate partners to elevate Hong Kong’s status as a leading global innovation hub.

The Head of the Institute for Translational Research of HKSTP highlighted the scope of the HKSTP MedTech Co-Create platform, which encompasses a vast network of partner companies and researchers covering various fields, including Stem Cell & Regenerative Medicine.

The platform’s goal is to build a comprehensive healthcare system that provides holistic applications for prevention, diagnosis, treatment, monitoring, and rehabilitation, fostering a patient-centric culture and delivering innovative Advanced Therapy Products.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.